Clinical trials: Genetic Obesity, open to volunteers
Colorectal Cancer, Early Onset Colorectal Cancer
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
An increase in early-onset colorectal cancers (eoCRC), defined as a CRC before 50 years, is confirmed globally. CRC pathogenesis has been associated with several risk factors (family history, germline pathogenic variants…
- Conditions
- Colorectal Cancer, Early Onset Colorectal Cancer, Diet Habit, Risk Reduction
- Trial name
- DEMETRA (NCT05732623)
- Testing
- Semi Quantitative Food Frequency Questionnaire (SQFFQ)
- Where
- 8 sites in United States, Finland and 4 more
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- San Raffaele University
Obesity
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
The goal of this clinical trial is to understand if genetic variations are associated with the amount of weight loss with diet and while taking an FDA-approved medication for weight loss.
- Trial name
- NCT05919797
- Testing
- Naltrexone-Bupropion Combination
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Columbia University
Breast Cancer Risk, Cardiovascular Disease Risk
The RISC Registry--Risk Informed Screening Registry
Chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States. Six in ten adults have one chronic disease; 4 in 10 have two or more.
- Conditions
- Breast Cancer Risk, Cardiovascular Disease Risk, Cardiometabolic Risk, Diabetes
- Trial name
- RISC (NCT05848856)
- Testing
- Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Precision Health Equity Initiative
Prader-Willi Syndrome
A Study of Pitolisant in Patients With Prader-Willi Syndrome
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome.
- Trial name
- NCT06366464
- Testing
- Pitolisant tablet
- Where
- 57 sites in United States, Australia and 11 more
- Volunteers
- 134 people
- Sponsor
- Harmony Biosciences Management, Inc.
Skin Laxity, Localized Adiposity
Prospective Evaluation of Recombinant Pbserum Plus® and Pbserum HA 2.0® in Aesthetic and Regenerative Bioremodeling
This study will evaluate the efficacy and safety of recombinant enzymes contained in pbserum Plus® and pbserum HA 2.0® for aesthetic and regenerative tissue bioremodeling.
- Conditions
- Skin Laxity, Localized Adiposity, Cellulite, Tissue Fibrosis
- Trial name
- NCT07908953
- Testing
- Recombinant Hyaluronic Acid (pbserum HA 2.0®), pbserum Plus®
- Where
- Brazil
- Volunteers
- 150 people
- Sponsor
- Antony Barbosa Institute
Bariatric Surgery Candidate, Obesity
Periodontal Assessment of a Bariatric Care Population
Our primary aim is to investigate the prevalence and severity of Periodonotal Disease (PD) in a population of obese patients. Our secondary objectives are to: Investigate inflammatory biomarkers that have been associated with PD…
- Trial name
- Bariatric (NCT04851470)
- Where
- 4 sites in United Kingdom
- Volunteers
- 394 people
- Sponsor
- Queen Mary University of London
Pseudohypoparathyroidism Type 1a, Obesity
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
The investigators plan to test the efficacy and safey of 6-months of open-label setmelanotide to treat obesity in a single patient with pseudohypoparathyroidism type 1a due to a GNAS mutation.
- Trial name
- NCT07496463
- Testing
- Setmelanotide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Massachusetts General Hospital
Prader-Willi Syndrome
The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics
Prader-Willi syndrome (PWS) is a rare genetic disease, with hyperappetite and severe obesity. At present, there is no effective drugs and interventions to help control the appetite of PWS patients.
- Trial name
- NCT05791604
- Testing
- probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG, Prebiotics with galactomannan and oligofructose
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Children's Hospital of Fudan University
Silver Russell Syndrome, Beckwith-Wiedemann Syndrome
IDMet (RaDiCo Cohort) (RaDiCo-IDMet)
The goal of this observational study is to describe the natural history of imprinting disorders (IDs) according to their metabolic profile in all patients (adults and children) affected with an ID regardless of the severity of…
- Conditions
- Silver Russell Syndrome, Beckwith-Wiedemann Syndrome, Transient Neonatal Diabetes Mellitus, Angelman Syndrome
- Trial name
- IDMet (NCT05945576)
- Where
- 20 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Prader-Willi Syndrome
Register of Patients With Prader-Willi Syndrome
Prader-Willi Syndrome (PWS) is a rare syndrome with a prevalence of 15 to 20 000 at birth. PWS represents a large fraction of mental retardation syndromes due to a genetic cause and the most frequent cause of genetic obesity.
- Trial name
- NCT02829684
- Testing
- Data collection
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Toulouse
Elastography, Shear Wave Elastography
HIBOC = Hepatic Imaging Biomarkers in Obese Children
The goal of this prospective, diagnostic observational study is to learn about how imaging based markers for components of liver disease appear in children with obesity.
- Conditions
- Elastography, Shear Wave Elastography, Shear Wave Dispersion, Attenuation Imaging
- Trial name
- NCT06463223
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Sahlgrenska University Hospital
Prader-Willi Syndrome
A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.
The goal of this clinical trial is to evaluate the safety and effects of a new drug called BMB-101 in people with Prader-Willi Syndrome (PWS).
- Trial name
- NCT07266324
- Testing
- BMB-101
- Where
- 2 sites in Australia
- Volunteers
- 16 people
- Sponsor
- Bright Minds Biosciences Pty Ltd
Prader-Willi Syndrome
Regulating Together for Prader-Willi Syndrome: A Group Behavioral Therapy for Emotion Dysregulation
The goal of this study is to help teens with Prader-Willi Syndrome (PWS) and their families learn practical strategies for managing issues like irritability, meltdowns, and anxiety.
- Trial name
- RT-PWS (NCT07607730)
- Testing
- Regulating Together group therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Mercy Hospital Kansas City
Obesity and Obesity-related Medical Conditions, Diabetes
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
The purpose of this research study is to validate (check the accuracy of) laboratory assays, intravenous catheter insertion, and equipment or devices and their reproducibility, which is necessary to perform high quality research…
- Conditions
- Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure
- Trial name
- VALD (NCT07083557)
- Testing
- Endothelial cell collection
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bettina Mittendorfer
Depression, Depressive Disorder
Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation
The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy.
- Conditions
- Depression, Depressive Disorder, Overweight or Obesity, Depressive Symptoms
- Trial name
- NCT07654179
- Testing
- Metformin, Antidepressant Therapy
- Where
- 2 sites in Pakistan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Riphah International University
Obesity Prevention
Better4All Personalized Intervention
The BETTER4U (Preventing obesity through Biologically and bEhaviorally Tailored inTERventions for you) project, funded by the European Union, aims to address obesity through biologically and behaviourally tailored interventions.
- Trial name
- BETTER4ALL (NCT06997510)
- Testing
- Personalized lifestyle recommendations based on artificial intelligence (AI) and polygenic risk scores (PRS), Standard care: lifestyle counselling, healthy eating leaflet, and hyocaloric diet targeting ≥5% weight loss in 6 months.
- Where
- 7 sites in Cyprus, France and 5 more
- Volunteers
- 1,022 people
- Sponsor
- Harokopio University
Prader-Willi Syndrome
Autistic Symptomatology and Sensory Profile in Children With Prader-Willi Syndrome
Prader-Willi Syndrome (PWS) is a rare neurodevelopmental disorder stemming from genetic damage in the 15q11-q13 region, leading to hypothalamic dysfunction.
- Trial name
- CASSPER (NCT06877715)
- Testing
- psychological and sensorial tests
- Where
- France
- Volunteers
- 75 people
- Sponsor
- University Hospital, Toulouse
Bardet Biedl Syndrome (BBS), Bardet Biedl Syndrome
Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity
Bardet-Biedl syndrome (BBS) and other rare disorders associated with impairment of the melanocortin-4 receptor (MC4R) pathway are characterized by severe early-onset obesity, hyperphagia, and substantial morbidity.
- Conditions
- Bardet Biedl Syndrome (BBS), Bardet Biedl Syndrome, Bardet-Biedl Syndrome (BBS), Alstrom Syndrome
- Trial name
- REAL-MC4 (NCT07674290)
- Testing
- Setmelanotide
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Tom Hühne
Atrial Fibrillation, Coronary Heart Disease
EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality
Health inequality and genetic disparity are a significant issue in the United Kingdom (UK). This study focuses on diseases that are associated with significant morbidity and mortality in the UK, and specifically examines the…
- Conditions
- Atrial Fibrillation, Coronary Heart Disease, Cardiovascular Diseases, Heart Failure
- Trial name
- EMPOWER (NCT03987633)
- Where
- United Kingdom
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- Future Genetics Limited
Precocious Puberty, Overweight and Obesity
Overweight and Obesity and Puberty Development Cohort Study
Precocious puberty and childhood overweight and obesity are important public health problems that both had adverse effects, which including psychological symptom in childhood, short final height or reproductive dysfunction in…
- Trial name
- NCT04113070
- Testing
- Anthropometric measuring, Growth environment evaluation
- Where
- China
- Volunteers
- 14,100 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine